Raymond James reiterates Scholar Rock stock rating on MAA resubmission
Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.
How this was made
The 30-second read
Why it matters
Analyst upgrades reflect confidence in the resubmission and the commercial potential of ISEMBYLD, potentially boosting the stock.
Market read
The analyst upgrades collectively raise expectations for SRRK, likely prompting short‑term buying interest.
What to watch
Potential competition from other SMA therapies and the reliance on a single European filing.
Background
Scholar Rock (SRRK) is a biotech focused on spinal muscular atrophy therapies. The company recently withdrew its MAA, then resubmitted it with a new fill‑finish site.
Ticker impact
Raymond James reiterated a Strong Buy rating and raised the price target to $72 for Scholar Rock after its MAA resubmission update.
likely upward pressure as investors price in the higher target.
The new rating and $72 target are fresh analyst actions that can move the stock in the short term.
Market effects
Positive signal for biotech/rare‑disease sector as a peer receives a rating upgrade.
Limited to U.S. biotech investors.
Minor; primarily affects SRRK shareholders.
Counterpoint
The rating may be premature if the EU MAA opinion is delayed beyond H1‑2027.
Key entities
- AnalystRaymond James
Reiterated Strong Buy and $72 price target.
- AnalystPiper Sandler
Overweight rating with $75 target.
